



VIVO Biobank : Guidelines

VIVO Biobank is funded by Cancer Research UK and Blood Cancer UK and managed by a Steering Committee which oversees appropriate legal, ethical and research governance.

VIVO Biobank contains samples from children and young people diagnosed with cancer. This includes diagnostic, follow-up and relapse samples. VIVO Biobank also contains HLA typed normal umbilical cord blood donations.

Samples can only be obtained from VIVO Biobank for approved peer reviewed and fully funded research projects.

Applications will be considered on receipt for approval by the VIVO Biobank Sample and Data Access Committee. There are no application deadlines.

The investigator will be liable for ensuring the proper and safe use, handling, storage and return of samples in accordance with all applicable laws and regulations including the Human Tissue Act 2004:
<http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/legislation/humantissueact.cfm>.

Investigators in receipt of samples may only use these samples for the purpose approved by SDAC unless additional specific approval has been granted by VIVO Biobank.

The release of samples is subject to a Material Transfer Agreement.

Whilst every effort will be made to provide samples of the highest quality and viability VIVO Biobank cannot guarantee (nor be held responsible) for their suitability for research.

The investigator is responsible for meeting the shipment costs.

Investigators must provide an annual report on the progress of the study to the VIVO Biobank Steering Committee. A more comprehensive final report should also be provided on completion of the study. Failure to submit annual reports will disqualify the investigator from further access to the VIVO Biobank.

If additional samples appropriate for use in the study are deposited in VIVO Biobank after the study has been approved, the investigator **cannot** request release of the samples without first providing a written proposal to the Chair of the Steering Committee. The request must provide full justification for requiring the additional samples.

Any samples remaining after completion of the project may not be used for other projects unless specific approval has been granted by VIVO Biobank. Such samples should be stored under appropriate conditions for future use by VIVO Biobank. A full report detailing which samples have been exhausted and which remain must be submitted to the VIVO Biobank Steering Committee with the final project report

The Steering Committee reserves the right to refuse the release or to recall samples at any time.

All publications using VIVO Biobank samples must contain the following acknowledgement:
"Samples and data used in this study were provided by VIVO Biobank, supported by Cancer Research UK & Blood Cancer UK (Grant no. CRCPSC-Dec21\100003)"